Acuitas Investments LLC Cuts Stock Position in Progyny, Inc. $PGNY

Acuitas Investments LLC cut its holdings in Progyny, Inc. (NASDAQ:PGNY) by 23.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 131,725 shares of the company’s stock after selling 41,007 shares during the quarter. Progyny accounts for approximately 2.3% of Acuitas Investments LLC’s investment portfolio, making the stock its 16th largest position. Acuitas Investments LLC’s holdings in Progyny were worth $2,898,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. International Assets Investment Management LLC purchased a new position in shares of Progyny in the second quarter valued at $3,398,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Progyny in the second quarter worth $433,000. Nordea Investment Management AB lifted its position in Progyny by 0.6% in the second quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock worth $4,052,000 after buying an additional 1,140 shares during the last quarter. Truist Financial Corp lifted its position in Progyny by 47.0% in the second quarter. Truist Financial Corp now owns 23,470 shares of the company’s stock worth $516,000 after buying an additional 7,499 shares during the last quarter. Finally, GC Wealth Management RIA LLC bought a new stake in Progyny in the second quarter worth $647,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Progyny

In other news, Director Kevin K. Gordon sold 2,500 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at approximately $275,522.04. The trade was a 16.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Allison Swartz sold 2,398 shares of the business’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,895 shares of company stock worth $179,311 over the last 90 days. Company insiders own 9.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PGNY. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Truist Financial raised their price target on Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. lifted their target price on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Progyny Trading Up 1.7%

Shares of Progyny stock opened at $19.50 on Friday. The firm has a market cap of $1.68 billion, a P/E ratio of 33.05, a P/E/G ratio of 1.63 and a beta of 1.34. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76. The stock’s fifty day moving average price is $21.79 and its 200-day moving average price is $22.05.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm had revenue of $332.87 million for the quarter, compared to analysts’ expectations of $315.70 million. During the same quarter in the prior year, the business posted $0.17 EPS. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.